Get notified when VOR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVor Biopharma announces partner RemeGen wins two China approvals for telitacicept drug
Filed June 8, 2026 · Period ending June 8, 2026 · ~1 min read
Key Changes
-
high
RemeGen received conditional approval from China's NMPA to sell telitacicept for IgA nephropathy, a kidney disease. Conditional approval allows commercialization while confirmatory studies continue.
Item 8.01 view on EDGAR → -
high
RemeGen also received full NMPA approval for telitacicept to treat Sjögren's disease, an autoimmune disorder. This is the drug's second approved indication in China.
Item 8.01 view on EDGAR → -
medium
The dual approvals expand telitacicept's commercial opportunity in China and may generate milestone payments or royalties for Vor depending on partnership terms.
8-K: Partner milestone verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (THRM 10-Q) is open in full — no account needed.
Partner
Trade VOR commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify